Will Biologics Surpass Small Molecules In The Pharmaceutical Race?
The first biologics drug, humanized insulin (5.8 kDa), became available in 1982 following the advent of biotechnology, and it marked …
#Thought-provoking
How To Be Ready For Future Pandemics?
What do antibiotic-resistant bacteria (“superbugs”) and coronaviruses have in common? They both can kill lots of people globally, and they …
The Evolution Of Pharmaceutical R&D Model
There is a plethora of analytics reports, including ones by Deloitte, DKV Global, and Ernst and Young, all pointing out …
Current State of AI in Pharma: Key Achievements Beyond Hype
/Last update -- 24 Dec 2019/ A background context -- opportunities and challenges Current widespread interest towards artificial intelligence (AI) and …
The Growth Imperative: Why The Next Big Pharma Competitor Could Be Google Or Apple
In a seminal work published by McKinsey & Company – The Granularity of Growth, a detailed study of the performance …
Antibiotic Research and Development - Public vs. Private Funding
Over the past decade, pull incentives as a solution to the broken antibiotic market have been proposed to entice companies …
Will 2019 Bring Positive Signals for the Declining Antibiotics R&D Market?
Antibiotic R&D has had a particularly bad year starting with The Medicines Company who abandoned their antibiotic R&D efforts and …
Get Ready For “Super-platforms” In Healthcare and Pharmaceutical Research
What is a super-platform? A “super-platform” is a term which describes a relatively new phenomenon in a modern technological world …
The “Why”, “How” and “When” of AI in Pharmaceutical Innovation
(Edited version of this post originally appeared in Forbes) “It is not the strongest of the species that survives, nor …
Outsourcing AI For Drug Discovery: Independent Expertise Is Key To Avoid Overhyped Claims
Investments in artificial intelligence (AI) for drug discovery are surging. Big Pharmas are throwing big bucks at AI. Sanofi signed …
